Ticker Details
Alnylam Pharmaceuticals, Inc. Alnylam Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in developing novel therapeutics based on RNA interference, or RNAi. RNAi is a naturally occurring biological pathway within cells for regulating the expression of specific genes.
IPO Date:	May 28, 2004
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$41.76B
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$1.91 | 2.29%
Avg Daily Range (30 D):	$6.20 | 2.07%
Avg Daily Range (90 D):	$5.45 | 1.77%

Institutional Daily Volume
Avg Daily Volume:	.56M
Avg Daily Volume (30 D):	1.06M
Avg Daily Volume (90 D):	.93M

Trade Size
Avg Trade Size (Sh.):	72
Avg Trade Size (Sh.) (30 D):	30
Avg Trade Size (Sh.) (90 D):	29

Institutional Trades
Total Institutional Trades:	11,158
Avg Institutional Trade:	$8.43M
Avg Institutional Trade (30 D):	$23.31M
Avg Institutional Trade (90 D):	$23.75M
Avg Institutional Trade Volume:	.05M
Avg Institutional Trades (Per Day):	3

Market Closing Trades
Avg Closing Trade:	$15.67M
Avg Closing Trade (30 D):	$70.33M
Avg Closing Trade (90 D):	$63.32M
Avg Closing Volume:	88.67K

News

Jul 7, 2026 @ 10:42 AM Transthyretin Amyloidosis Treatment Market Size to... Source: Sns Insider

Jul 2, 2026 @ 10:33 AM Wall Street Thinks This Biotech Stock Can Soar 45%... Source: James Halley

May 18, 2026 @ 6:33 PM Protein Synthesis Research Market to Reach $42.8 B... Source: Bcc Research

May 14, 2026 @ 5:00 PM Oligonucleotides Clinical Trial Drug Development P... Source: Delveinsight

Mar 17, 2026 @ 11:07 AM The $3B Biotech With Two Shots On Goal Source: Gav Blaxberg

Financials
	TTM	Q4 2025	FY 2025
Basic EPS	$2.39	$.84	$2.39
Diluted EPS	$2.33	$.82	$2.33
Revenue	$3.71B	$1.1B	$3.71B
Gross Profit	$3.04B	$829.31M	$3.04B
Net Income / Loss	$313.75M	$111.54M	$313.75M
Operating Income / Loss	$501.58M	$131.72M	$501.58M
Cost of Revenue	$677.17M	$267.72M	$677.17M
Net Cash Flow	$690.16M	$166.01M	$690.16M
PE Ratio